ArticleJAMA psychiatry2023
Association Between Retinal Features From Multimodal Imaging and Schizophrenia.
Article in JAMA psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography.Molecular psychiatry · 2024Pooled it
- Visual remediation of contrast processing impairments in schizophrenia: A preliminary clinical trial.Schizophrenia research · 2024Trial
- Estimating Accelerated Retinal Decline in Mental Health Disorders Through Normative Modeling.Schizophrenia bulletin · 2026Article
- FunduSegmenter: Leveraging the RETFound Foundation Model for Joint Optic Disc and Optic Cup Segmentation in Retinal Fundus Images.Translational vision science & technology · 2026Article
- Retinal cytoarchitectural alterations across the psychosis spectrum and their correlates with cognition: a UK biobank nested case-control study.Molecular psychiatry · 2026Article
- Brain-body interactions in systemic diseases: a survey from an imaging perspective.MedScience · 2026Review
- Severity-dependent fronto-cingulate network compensation of immune-dependent caudate-insula dysconnectivity in bipolar II depression.Research square · 2026Article
- Can the Posterior Segment Findings of the Eye and Serum Microbiota Metabolites Be a Biomarker in Schizophrenia?Medicina (Kaunas, Lithuania) · 2026Article
- Understanding pre-training data effects in retinal foundation models using two large fundus cohorts.Nature communications · 2026Article
- The Retinal Age Gap as a Marker of Accelerated Aging in the Early Course of Schizophrenia.Schizophrenia bulletin · 2026Article
- Oculomics: advances and perspectives from traditional Chinese medicine to modern multimodal biomarkers.International journal of ophthalmology · 2026Review
- Article
- Optic disc morphometrics as a potential ocular biomarker for depression: evidence from two cross-sectional cohort studies.Translational psychiatry · 2025Article
- VascX Models: Deep Ensembles for Retinal Vascular Analysis From Color Fundus Images.Translational vision science & technology · 2025Article
- Changes in Retinal Vasculature Phenotype and Choroidal Blood Flow at High Altitude in Healthy Lowlanders.Investigative ophthalmology & visual science · 2025Article
- Genetic Analysis of Retinal Cell Types in Neuropsychiatric Disorders.JAMA psychiatry · 2025Article
- Preclinical Retinal Disease Models: Applications in Drug Development and Translational Research.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cardiovascular comorbidities in Chinese inpatients with schizophrenia spectrum disorders.Schizophrenia (Heidelberg, Germany) · 2025Article
- Multi-omic spatial effects on high-resolution AI-derived retinal thickness.Nature communications · 2025Article
- Genetic susceptibility to schizophrenia through neuroinflammatory pathways associated with retinal thinness.Nature. Mental health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Importance: The potential association of schizophrenia with distinct retinal changes is of clinical interest but has been challenging to investigate because of a lack of sufficiently large and detailed cohorts. Objective: To investigate the association between retinal biomarkers from multimodal imaging (oculomics) and schizophrenia in a large real-world population. Design, Setting, and Participants: This cross-sectional analysis used data from a retrospective cohort of 154 830 patients 40 years and older from the AlzEye study, which linked ophthalmic data with hospital admission data across England. Patients attended Moorfields Eye Hospital, a secondary care ophthalmic hospital with a principal central site, 4 district hubs, and 5 satellite clinics in and around London, United Kingdom, and had retinal imaging during the study period (January 2008 and April 2018). Data were analyzed from January 2022 to July 2022. Main Outcomes and Measures: Retinovascular and optic nerve indices were computed from color fundus photography. Macular retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (mGC-IPL) thicknesses were extracted from optical coherence tomography. Linear mixed-effects models were used to examine the association between schizophrenia and retinal biomarkers. Results: A total of 485 individuals (747 eyes) with schizophrenia (mean [SD] age, 64.9 years [12.2]; 258 [53.2%] female) and 100 931 individuals (165 400 eyes) without schizophrenia (mean age, 65.9 years [13.7]; 53 253 [52.8%] female) were included after images underwent quality control and potentially confounding conditions were excluded. Individuals with schizophrenia were more likely to have hypertension (407 [83.9%] vs 49 971 [48.0%]) and diabetes (364 [75.1%] vs 28 762 [27.6%]). The schizophrenia group had thinner mGC-IPL (-4.05 μm, 95% CI, -5.40 to -2.69; P = 5.4 × 10-9), which persisted when investigating only patients without diabetes (-3.99 μm; 95% CI, -6.67 to -1.30; P = .004) or just those 55 years and younger (-2.90 μm; 95% CI, -5.55 to -0.24; P = .03). On adjusted analysis, retinal fractal dimension among vascular variables was reduced in individuals with schizophrenia (-0.14 units; 95% CI, -0.22 to -0.05; P = .001), although this was not present when excluding patients with diabetes. Conclusions and Relevance: In this study, patients with schizophrenia had measurable differences in neural and vascular integrity of the retina. Differences in retinal vasculature were mostly secondary to the higher prevalence of diabetes and hypertension in patients with schizophrenia. The role of retinal features as adjunct outcomes in patients with schizophrenia warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.